SLC12A5 and brain injury: In various pathophysiological models involving reduced KCC2 activity, such as SCI, bilateral hemisection of the spinal cord, traumatic brain injury, PNI, and pressure models, administration of KCC2 agonist CLP290 has been found to significantly increase KCC2 activity and/or membrane expression and improve neuropathic pain, spasticity, and motor function.22, 41, 42, 43, 44, 45, 46